HLS Therapeutics Inc (TSE:HLS)

TSX:HLS

HLS

HLS Therapeutics Inc

RESEARCH TOOLSreports

Want to see TSE:HLS full AI Analyst Report?

HLS Therapeutics Inc (HLS) Price & Analysis

45 Followers

HLS Stock Chart & Stats

C$4.65

C$0.04(1.06%)

At close: Jan 08 4:00 PM EST

C$4.65

C$0.04(1.06%)

Day’s Range― - ―

52-Week RangeC$4.22 - C$5.77

Previous CloseN/A

Volume4.75K

Average Volume (3M)19.90K

Market Cap

C$136.04M

Enterprise ValueC$133.66M

Total Cash (Recent Filing)C$12.33M

Total Debt (Recent Filing)C$43.96M

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Aug 06, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding31,273,682

10 Day Avg. Volume21,807

30 Day Avg. Volume19,898

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)1.80

Price to Sales (P/S)1.96

P/FCF Ratio7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$7.15

Price Target Upside53.76% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.27

Revenue Forecast (FY)C$58.05M

Bulls Say, Bears Say

Bulls Say

Cash GenerationSustained operating cash flow and very strong free cash flow provide durable internal funding to support commercialization, acquisitions, and debt reduction. This cash conversion cushions the business versus accounting losses and enables strategic flexibility over the next several quarters.

Asset-light Commercialization ModelThe company's model of acquiring or licensing late-life-cycle branded drugs and using its commercial infrastructure reduces R&D risk and accelerates time-to-revenue. This repeatable BD-led approach supports predictable product cash flows if deal sourcing and commercialization capabilities remain intact.

Improved Margins (gross/EBITDA)Sharply improved gross margin and healthy EBITDA margins point to efficient product economics and pricing power on marketed products. These operating-margin improvements underpin sustained cash generation, even if accounting net income remains negative, improving long-term resilience.

Bears Say

Persistent Net Losses & Negative ROEMaterial negative net margin and negative return on equity indicate the business is not yet producing accounting profits; over time, continued losses can erode shareholder equity, restrict capital options, and hinder trust from lenders and partners unless profitability inflects.

Revenue VolatilityRevenue has been uneven, with a down year and a period of flat sales before modest recent growth. Reliance on product lifecycle timing and deal-driven revenue makes top-line consistency vulnerable, complicating forecasting and the ability to scale fixed commercial costs sustainably.

Debt Coverage RiskAlthough cash flow is strong, coverage of total debt is only about 0.65x, meaning deleveraging depends on maintaining or increasing cash generation. A prolonged cash slowdown or larger financing needs could pressure liquidity and raise refinancing risk amid ongoing accounting losses.

HLS Therapeutics Inc News

HLS Therapeutics resumed with a Hold at Canaccord

Canaccord resumed coverage of HLS Therapeutics (HLTRF) with a Hold rating and C$5 price target Published first on...

23d ago

HLS Therapeutics: Buy Rating Reiterated as Analyst Sees Nilemdo Upside with Unchanged $12 Price Target

Analyst David Martin PhD from Bloom Burton maintained a Buy rating on HLS Therapeutics Inc and keeping the...

23d ago

HLS Earnings this Week: How Will it Perform?

Hls Therapeutics (HLS) is scheduled to report 1st quarter earnings on 05/15/2026, before the market opens. Regarding Q1...

29d ago

HLS Therapeutics to Highlight CNS and Cardiovascular Portfolio at Bloom Burton Investor Conference

HLS Therapeutics Inc ( ($TSE:HLS) ) has shared an announcement. HLS Therapeutics Inc. will showcase its strategy and...

2M ago

HLS Therapeutics: Near-Term Softness Masking NILEMDO-Driven Growth Upside, Supporting Buy Rating

HLS Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst on March 13. Analyst...

3M ago

HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel

Stifel lowered the firm’s price target on HLS Therapeutics (HLTRF) to C$4.45 from C$4.75 and keeps a Hold...

3M ago

HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio

HLS Therapeutics Inc ( ($TSE:HLS) ) has provided an announcement. HLS Therapeutics reported fiscal 2025 revenue of $55.5...

3M ago

Is HLS a Buy, Before Earnings?

Hls Therapeutics (HLS) is scheduled to report 4th quarter earnings on 03/12/2026, before the market opens. Regarding Q4...

3M ago

HLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs

HLS Therapeutics Inc ( ($TSE:HLS) ) has provided an update. HLS Therapeutics has launched NILEMDO (bempedoic acid) across...

3M ago

HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs

An update from HLS Therapeutics Inc ( ($TSE:HLS) ) is now available. HLS Therapeutics has launched NILEMDO, a...

3M ago

HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call

HLS Therapeutics Inc ( ($TSE:HLS) ) has shared an update. HLS Therapeutics Inc. will release its fiscal 2025...

3M ago

HLS Therapeutics price target raised to C$4.75 from C$4 at Stifel

Stifel raised the firm’s price target on HLS Therapeutics (HLTRF) to C$4.75 from C$4 and keeps a Hold...

6M ago

HLS FAQ

What was HLS Therapeutics Inc’s price range in the past 12 months?

HLS Therapeutics Inc lowest stock price was C$4.22 and its highest was C$5.76 in the past 12 months.

What is HLS Therapeutics Inc’s market cap?

HLS Therapeutics Inc’s market cap is C$136.04M.

When is HLS Therapeutics Inc’s upcoming earnings report date?

HLS Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.

How were HLS Therapeutics Inc’s earnings last quarter?

HLS Therapeutics Inc released its earnings results on Mar 12, 2026. The company reported -C$0.056 earnings per share for the quarter, missing the consensus estimate of -C$0.042 by -C$0.014.

Is HLS Therapeutics Inc overvalued?

According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does HLS Therapeutics Inc pay dividends?

HLS Therapeutics Inc pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here

What is HLS Therapeutics Inc’s EPS estimate?

HLS Therapeutics Inc’s EPS estimate is -0.11.

How many shares outstanding does HLS Therapeutics Inc have?

HLS Therapeutics Inc has 31,273,682 shares outstanding.

What happened to HLS Therapeutics Inc’s price movement after its last earnings report?

HLS Therapeutics Inc reported an EPS of -C$0.056 in its last earnings report, missing expectations of -C$0.042. Following the earnings report the stock price went up 0.468%.

Which hedge fund is a major shareholder of HLS Therapeutics Inc?

Currently, no hedge funds are holding shares in TSE:HLS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

HLS Therapeutics Inc

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

HLS Therapeutics Inc (HLS) Earnings & Revenues

Historic Earnings Reports

HLS Stock 12 Month Forecast

Average Price Target

C$7.15

▲(53.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"C$3","8":"C$8","13":"C$13","5.5":"C$5.5","10.5":"C$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.1499999999999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$7.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$4.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.5,8,10.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.45,5.030769230769231,5.611538461538462,6.1923076923076925,6.773076923076923,7.3538461538461535,7.934615384615384,8.515384615384615,9.096153846153847,9.676923076923076,10.257692307692306,10.838461538461537,11.419230769230769,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.45,4.657692307692308,4.865384615384616,5.073076923076923,5.280769230769231,5.4884615384615385,5.696153846153846,5.903846153846153,6.111538461538461,6.319230769230769,6.526923076923077,6.734615384615385,6.942307692307692,{"y":7.1499999999999995,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.45,4.45,4.45,4.45,4.45,4.45,4.45,4.45,4.45,4.45,4.45,4.45,4.45,{"y":4.45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >